What Do Physicians and Patients Think About ADCs as Cancer Treatment?
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar safety profile that requires multidisciplinary collaboration to optimally treat.
Daratumumab Approval May Be “Game Changer” in High-Risk Smoldering Myeloma
The approval of daratumumab validates the notion of using limited therapy to help delay progression from smoldering disease to multiple myeloma.
Palazestrant Combo Shows Preliminary Activity in ER+/HER2– Breast Cancer
The safety profile of palazestrant plus ribociclib in a phase 1b trial was comparable to prior reports of each individual agent.
FDA OKs Subcutaneous Daratumumab in High-Risk Smoldering Multiple Myeloma
Data from the phase 3 AQUILA study support the FDA approval of subcutaneous daratumumab in this population with smoldering multiple myeloma.
What Were The Most Impactful GU Oncology Data From ESMO 2025?
Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.
UGN-103 Exhibits Durable Responses in Recurrent LG-IR-NMIBC
The FDA agreed that data from the UTOPIA trial, with UGN-103 demonstrating a 77.8% 3-month CR rate in patients with LG-IR-NMIBC, support an NDA submission.
ACRO Issues Statement on 2026 Physician Fee Schedule Final Rule
Due to certain errors in the 2026 PFS Final Rule pre-publication, ACRO has issued a statement while awaiting the publication of the 2026 HOPPS Final Rule.
How ADCs are Replacing Chemotherapy as Breast Cancer Treatment
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Outlining a Radioembolization/Chemotherapy Regimen for NET Liver Metastases
A simulation procedure helped to ascertain chemotherapy tolerability before administering radioembolization therapy for NETs with liver metastases.
Neoadjuvant Nivolumab/Ipilimumab Shows Superior EFS in Resectable Melanoma
The 24-month RFS rates were 95.1%, 81.2%, 69.4%, and 48.4% in patients with stage III melanoma who experienced a pCR, near pCR, pPR, pNR, respectively.
Searching for Synergy in Liver-Dominant Neuroendocrine Tumors
The addition of radioembolization to radiosensitizing chemotherapy may help concurrently treat patients with liver tumors and disease outside the liver.
How Do GLP-1 Agents Factor Into Neuroendocrine Tumor Care Strategies?
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Trial Assessing Savolitinib/Osimertinib in NSCLC Completes Enrollment
Topline data are expected to be available in the first half of 2026 after the submission of results for presentation at a medical conference.
Lower EDIC May Improve Local Tumor Control in Lung Cancer
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
How Will the Continued Success of ADCs in Breast Cancer Be Propelled in the Future?
Aditya Bardia, MD, highlights the successes and challenges associated with ADC treatments in breast cancer.
Novel TLR Coagonist Combo Shows Responses in Stage IV NSCLC
Phase 2 data showed no dose-limiting toxicities with EIK1001 plus pembrolizumab in patients with advanced non–small cell lung cancer.
FDA Clears IND Application for Novel IL-2 Agent in Advanced NSCLC
ILKN421H plus pembrolizumab previously showed antitumor activity among patients with frontline non–small cell lung cancer in a phase 1 trial.
EDIC Displays Continuous Evolution as Variable in EOT Grade 3 Lymphopenia
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
Lifileucel Confers Durable Responses in Pretreated Advanced NSCLC Type
Improvements in safety were observed without compromising efficacy after non-myeloablative lymphodepletion was reduced in this NSCLC population.
How Can Oncology Staffing Shortages Be Remedied?
Manali Patel, MD, MPH, MS, FASCO, discusses current gaps, projected needs, and actionable strategies for the US hematology and medical oncology workforce.
How Can Cancer Cachexia Be Treated? Molecular Subtypes May Be Key
Cancer cachexia can be deadly, and due to AEs or the tumor itself, scientists are now looking at molecular subtypes to inform treatment decisions.
Muscle RNome Analysis Reveals 2 Molecular Subtypes Associated With Cancer Cachexia
Vickie Baracos, PhD, determined 2 highly coherent molecular subtypes in human muscle from patients with cancer at risk of cachexia.
Forming CUTNETs: A Joint Venture Between Surgery and Oncology in NETs
Considering historical trends of underpowered data in NET surgical studies, CUTNETs established a collaboration of surgical teams to better power research.
Atezolizumab Combo Elicits No Significant Benefit in Ovarian Cancer
Phase 3 data demonstrate PD-L1 positivity and BRCA mutation status as prognostic for improved overall survival regardless of treatment arm.
Glofitamab/Polatuzumab Vedotin Exhibits Response Durability in R/R LBCL
The glofitamab-based regimen displayed manageable safety, with minimal high-grade CRS and infrequent low-grade ICANS, in relapsed/refractory LBCL.
Short-Course Radiation May Be Feasible in Older Rectal Cancer Population
A shorter course of radiotherapy may provide similar oncological outcomes as long-course treatment for older patients with locally advanced rectal cancer.
How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap
Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.
Zurletrectinib Generates Responses in Advanced NTRK Fusion Solid Tumors
No dose-limiting toxicities were observed in the phase 1/2 trial evaluating zurletrectinib in patients with NTRK/ROS1-driven malignancies.
Sac-TMT Combo Produces Encouraging Activity in Pretreated Metastatic CRPC
Data from a phase 2 study support further development of sacituzumab tirumotecan plus pembrolizumab in metastatic castration-resistant prostate cancer.
Molecular Insights Into Cancer Cachexia: An Evolution in Identifying the Syndrome
Vickie Baracos, PhD, discusses recent results that investigate cancer cachexia and how the RNome of the muscle plays a role.
![“[This approval] will be a quite dramatic change in our philosophy and practice in multiple myeloma," according to Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F3cab3ada4c023b68c118240a512e31d72a7f931b-1200x628.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“[This approval] will be a quite dramatic change in our philosophy and practice in multiple myeloma,\" according to Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO.")
